Hirotoshi Sakaguchi
Overview
Explore the profile of Hirotoshi Sakaguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim H, Ikuse T, Matsui T, Sakaguchi H, Ishiguro A, Shoji K
Pediatr Int
. 2024 Dec;
66(1):e15837.
PMID: 39692201
Background: Information on the etiology and prognosis for leukemoid reaction (LR) in children is still limited and little is known about the factors that distinguish LR from hematological malignancy (HM)....
2.
Kato I, Tomizawa D, Kato M, Hirabayashi S, Manabe A, Irie M, et al.
Transplant Cell Ther
. 2024 Dec;
31(2):86-96.
PMID: 39617098
Chimeric antigen receptor (CAR) T cells are a major new treatment option for children, adolescents, and young adults (CAYA) patients with relapsed and refractory (R/R) B cell acute lymphoblastic leukemia...
3.
Ikenobe N, Fujimori K, Gocho Y, Myojin S, Yamada M, Imadome K, et al.
EJHaem
. 2024 Oct;
5(5):1072-1075.
PMID: 39415920
Urgent haploidentical haematopoietic cell transplantation may be considered in cases of severe aplastic anaemia (SAA) without a human leukocyte antigen-matched donor and suffering from severe infection. However, deciding on allogeneic...
4.
Sakaguchi H, Taga T, Ishida H, Hama A, Okamoto Y, Sano H, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1621-1624.
PMID: 39174743
No abstract available.
5.
Miyamoto S, Niizato D, Tomomasa D, Nishimura A, Hoshino A, Kamiya T, et al.
J Clin Immunol
. 2024 May;
44(6):126.
PMID: 38773000
Alemtuzumab is used with reduced-toxicity conditioning (RTC) in allogeneic hematopoietic cell transplantation (HCT), demonstrating efficacy and feasibility for patients with inborn errors of immunity (IEI) in Western countries; however, the...
6.
Ishida H, Kawahara Y, Tomizawa D, Okamoto Y, Hama A, Cho Y, et al.
J Hematol Oncol
. 2024 Apr;
17(1):24.
PMID: 38679709
Although killer Ig-like receptor ligands (KIR-L) mismatch has been associated with alloreactive natural killer cell activity and potent graft-versus-leukemia (GVL) effect among adults with acute myeloid leukemia (AML), its role...
7.
Fujimori K, Ikenobe N, Gocho Y, Uchiyama T, Deguchi T, Sakaguchi H, et al.
Pediatr Blood Cancer
. 2024 Feb;
71(5):e30919.
PMID: 38407463
No abstract available.
8.
Iguchi A, Uchiyama T, Fujimori K, Gocho Y, Sakaguchi H, Deguchi T, et al.
Int J Hematol
. 2024 Jan;
119(3):334-337.
PMID: 38227075
HLA-haploidentical stem cell transplantation (haplo-SCT) using post-transplant high-dose cyclophosphamide (PT-CY) is an alternative choice when a suitable donors is unavailable. However, PT-CY is difficult in patients with Fanconi anemia (FA)...
9.
Sakaguchi H
Rinsho Ketsueki
. 2023 Dec;
64(11):1440-1446.
PMID: 38072432
The prognosis of B-cell acute lymphoblastic leukemia in children, adolescents, and young adults has improved significantly over the second half of the last century, with long-term survival rates reaching 90%,...
10.
Hirate T, Kitazawa H, Sakaguchi H, Akita N, Hasegawa C, Yamamoto K, et al.
Rinsho Ketsueki
. 2023 Nov;
64(10):1275-1279.
PMID: 37914240
A 16-year-old boy received an unrelated bone marrow transplant while in second remission of acute myeloid leukemia. He suffered from severe oral mucosal complications and had difficulty taking oral drugs...